Evidence map›Paper›PMID 36070241›Full record

ArticleBMJ open2021

Cohort profile: Copenhagen Hospital Biobank - Cardiovascular Disease Cohort (CHB-CVDC): Construction of a large-scale genetic cohort to facilitate a better understanding of heart diseases.

Ina H Laursen, Karina Banasik, Amalie D Haue, Oscar Petersen, Peter C Holm, David Westergaard, Henning Bundgaard, Søren Brunak, Ruth Frikke-Schmidt, Hilma Holm and 21 more

Open access · goldAbstract read
In one paragraph

Article in BMJ open, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
1.4field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it, 12 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

31 authors at 7 institutions in 2 countries.

Ina H LaursenDepartment of Clinical Immunology, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark.ORCID 0000-0002-9534-8581
Karina BanasikNovo Nordisk Foundation Center for Protein Research, University of Copenhagen, Copenhagen, Denmark karina.banasik@cpr.ku.dk.ORCID 0000-0003-2489-2499
Amalie D HaueNovo Nordisk Foundation Center for Protein Research, University of Copenhagen, Copenhagen, Denmark.ORCID 0000-0001-7656-7976
Oscar PetersenDepartment of Clinical Immunology, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark.
Peter C HolmNovo Nordisk Foundation Center for Protein Research, University of Copenhagen, Copenhagen, Denmark.
David WestergaardNovo Nordisk Foundation Center for Protein Research, University of Copenhagen, Copenhagen, Denmark.
Henning BundgaardDepartment of Cardiology, The Heart Center, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark.
Søren BrunakNovo Nordisk Foundation Center for Protein Research, University of Copenhagen, Copenhagen, Denmark.
Ruth Frikke-SchmidtDepartment of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark.
Hilma HolmdeCODE genetics, Reykjavik, Iceland.
Erik SørensenDepartment of Clinical Immunology, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark.
Lise W ThørnerDepartment of Clinical Immunology, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark.
Margit A H LarsenDepartment of Clinical Immunology, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark.
Michael SchwinnDepartment of Clinical Immunology, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark.
Lars KøberDepartment of Cardiology, The Heart Center, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark.
Christian Torp-PedersenDepartment of Clinical Investigation and Cardiology, Nordsjællands Hospital, Hillerød, Denmark.
Sisse R OstrowskiDepartment of Clinical Immunology, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark.
Christian ErikstrupDepartment of Clinical Immunology, Aarhus University Hospital, Aarhus, Denmark.
Mette NyegaardDepartment of Biomedicine, Aarhus University, Aarhus, Denmark.
Hreinn StefánssondeCODE genetics, Reykjavik, Iceland.
Arnaldur GylfasondeCODE genetics, Reykjavik, Iceland.
Florian ZinkdeCODE genetics, Reykjavik, Iceland.
G Bragi WaltersdeCODE genetics, Reykjavik, Iceland.ORCID 0000-0002-5415-6487
Asmundur OddssondeCODE genetics, Reykjavik, Iceland.
Guðmar ÞorleifssondeCODE genetics, Reykjavik, Iceland.
Gisli MássondeCODE genetics, Reykjavik, Iceland.
Unnur ThorsteinsdottirdeCODE genetics, Reykjavik, Iceland.
Daniel GudbjartssondeCODE genetics, Reykjavik, Iceland.
Ole B PedersenDepartment of Clinical Immunology, Zealand University Hospital Køge, Køge, Denmark.
Kári StefánssondeCODE genetics, Reykjavik, Iceland.
Henrik UllumDepartment of Clinical Immunology, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark.
deCODE Genetics (Iceland) · ISUniversity of Copenhagen · DKCopenhagen University Hospital · DKAarhus University · DKAarhus University Hospital · DKNordsjællands Hospital · DKZealand University Hospital Køge · DK

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeThe aim of Copenhagen Hospital Biobank-Cardiovascular Disease Cohort (CHB-CVDC) is to establish a cohort that can accelerate our understanding of CVD initiation and progression by jointly studying genetics, diagnoses, treatments and risk factors.

participantsThe CHB-CVDC is a large genomic cohort of patients with CVD. CHB-CVDC currently includes 96 308 patients. The cohort is part of CHB initiated in 2009 in the Capital Region of Denmark. CHB is continuously growing with ~40 000 samples/year. Patients in CHB were included in CHB-CVDC if they were above 18 years of age and assigned at least one cardiovascular diagnosis. Additionally, up-to 110 000 blood donors can be analysed jointly with CHB-CVDC. Linkage with the Danish National Health Registries, Electronic Patient Records, and Clinical Quality Databases allow up-to 41 years of medical history. All individuals are genotyped using the Infinium Global Screening Array from Illumina and imputed using a reference panel consisting of whole-genome sequence data from 8429 Danes along with 7146 samples from North-Western Europe. Currently, 39 539 of the patients are deceased. FINDINGS TO DATE: Here, we demonstrate the utility of the cohort by showing concordant effects between known variants and selected CVDs, that is, >93% concordance for coronary artery disease, atrial fibrillation, heart failure and cholesterol measurements and 85% concordance for hypertension. Furthermore, we evaluated multiple study designs and the validity of using Danish blood donors as part of CHB-CVDC. Lastly, CHB-CVDC has already made major contributions to studies of sick sinus syndrome and the role of phytosterols in development of atherosclerosis. FUTURE PLANS: In addition to genetics, electronic patient records, national socioeconomic and health registries extensively characterise each patient in CHB-CVDC and provides a promising framework for improved understanding of risk and protective variants. We aim to include other measurable biomarkers for example, proteins in CHB-CVDC making it a platform for multiomics cardiovascular studies.

Indexed as

Cardiovascular DiseasesHeart DiseasesBiological Specimen BanksCohort StudiesHospitalsHumanscardiologyepidemiologygenetics

Identifiers

PMID36070241
PMCPMC8719218
OpenAlexW4205162150

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.